Fig. 6

Nuclear translocation of PAHs and oxy-PAHs by AhR. a Cardiomyocytes were treated with control (DMSO), 10 μM of ANT, AQ, BaA, or BAQ and stained at the indicated time points with anti-AhR antibodies (red). Representative fluorescence images show the translocation of AhR in the nucleus. Scale bar, 400 μm. b Representative fluorescence images of cardiomyocytes with or without α-NF. The cells were stained with anti-AhR antibodies (red). c The expression levels of phospho-CaMKII and phospho-RyR2 in the absence or presence of AhR antagonists, α-NF (10 nM) and propranolol (10 μM), were analyzed by western blotting (n = 5). The protein levels were normalized against those of β-actin levels. d The expression of SERCA2a in the absence or presence of α-NF were analyzed by western blotting (n = 5). Protein levels were normalized against those of β-actin. All values are represented as mean ± SD. *P < 0.05 or **P < 0.01 compared with control